Clinical trials: Incurable Disease, open to volunteers
Hepatocellular Carcinoma
A Study of TACE in Combination With SHR-8068, Adebrelimab, and Bevacizumab Versus TACE in Participants With Incurable Hepatocellular Carcinoma
This is a multicenter, Phase 3 clinical trial to evaluate the efficacy and safety of SHR-8068, Adebrelimab, and Bevacizumab and TACE versus Placebo with TACE in incurable hepatocellular carcinoma.
- Trial name
- NCT07691762
- Testing
- SHR-8068 + Adebrelimab + Bevacizumab
- Where
- 2 sites in China
- Volunteers
- 690 people
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Solid Tumor, Unspecified, Adult, Haematological Malignancy
Proseq Cancer: Genomic Profiling in Patients With Incurable Cancer in Search for Targeted Treatment
Proseq Cancer is a precision medicine program based on in-house whole exome sequencing (WES) and RNA sequencing. The approved protocol allows for biobanking, registration of clinical and laboratory data, and sharing of genomic…
- Trial name
- NCT05695638
- Where
- Denmark
- Volunteers
- 3,000 people
- Sponsor
- Morten Ladekarl
GastroEsophageal Cancer, Incurable Disease
The Effect of exeRcise And Diet on Quality of Life in Patients With Incurable Cancer of Esophagus and Stomach (RADICES)
The survival of patients with incurable gastroesophageal cancer can extend over a year with anticancer therapy. However, the number of patients with deteriorating quality of life in this patient group steadily decreases over time…
- Trial name
- RADICES (NCT06138223)
- Testing
- Exercise intervention, Nutrition intervention
- Where
- 22 sites in Netherlands
- Volunteers
- 196 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
HCC - Hepatocellular Carcinoma
A Phase IIa, Single-arm, Open-label Clinical Study to Evaluate the Efficacy, Safety and PK of CVM-1118 in Combination With Sintilimab and TACE in Participants With Incurable/Non-metastatic HCC
This is a single-arm, open-label Phase IIa study designed to evaluate the efficacy, safety, and PK of CVM-1118 in combination with Sintilimab (Tyvyt ®) and TACE in participants with incurable/non-metastatic HCC.
- Trial name
- NCT07521852
- Testing
- CVM-1118 + Sintilimab + TACE
- Where
- 2 sites in China
- Volunteers
- 40 people
- Sponsor
- TaiRx, Inc.
Lung Carcinoma, Metastatic Lung Carcinoma
Novel INPUT Screening Tool to Improve Illness Understanding in Patients With Metastatic or Incurable Lung Cancer
This clinical trial compares the use of a new screening tool designed to evaluate patients' information needs, preferences, and illness understanding to the usual care to improve illness understanding in patients with lung cancer…
- Conditions
- Lung Carcinoma, Metastatic Lung Carcinoma, Stage IV Lung Cancer AJCC v8
- Trial name
- NCT06743308
- Testing
- Best Practice, Questionnaire Administration
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- M.D. Anderson Cancer Center
Hepatocellular Carcinoma
A Study of AK104+Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma
A study to evaluate cadonilimab (AK104) + lenvatinib in combination with transarterial chemoembolization (TACE) versus TACE in participants with incurable/non-metastatic hepatocellular carcinoma
- Trial name
- NCT06371157
- Testing
- AK104, Lenvatinib, TACE
- Where
- 4 sites in China
- Volunteers
- 469 people
- Sponsor
- Akeso
Lung Non-Small Cell Carcinoma
Telisotuzumab Vedotin and Osimertinib for the Treatment of Progressive, Incurable, Non Small Cell Lung Cancer
This phase II trial tests how well telisotuzumab vedotin and osimertinib works for the treatment of non small cell lung cancer that is growing, spreading, or getting worse (progressive) and for which no treatment is currently…
- Trial name
- NCT07323641
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Incurable Disease
Generating Novel Therapeutic Strategies Based on Evolutionary Tumor Board
This study will evaluate the ability of a multidisciplinary group, the Evolutionary Tumor Board (ETB), to develop therapeutic strategies in patients without curative options.
- Trial name
- NCT04343365
- Testing
- Evolutionary Tumor Board (ETB)
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute